Latest Coronary catheterization Stories
WATERLOO, Belgium, April 6, 2010 /PRNewswire/ -- Cordis Corporation announced that Christian M. Spaulding, M.D., Ph.D., FESC, FACC, has been named as Worldwide Vice President of Medical Affairs. In this role, he will be a key leader of the company's medical team, responsible for leading the company's global clinical strategy. Dr. Spaulding will assume the role on June 1, and will be based in Paris. "We are very pleased that a cardiologist of Dr. Spaulding's stature is joining...
Contributions of Society of Interventional Radiology members through medical patents, patent applications continue to alter medical landscape to improve patient careOver the past 40 years, more than 2,400 patents and patent applications"”pioneering modern medicine with the devices and drugs that advance minimally invasive treatments"”have been filed by members of the Society of Interventional Radiology. These innovations"”from the invention of angioplasty and the catheter-delivered...
It's time to re-think how patients are selected for cardiac catheterization, say doctors at Duke University Medical Center, after reporting in a new study that the invasive procedure found no significant coronary artery disease in nearly 60 percent of chest pain patients with no prior heart disease."Our data show that up to two thirds of the patients undergoing invasive cardiac catheterization are found not have significant obstructive disease," says Manesh Patel, MD, a cardiologist...
Newly published data shows using a Respiratory Modulation Response (RMR) is a novel, non-invasive measure to quickly and accurately detect the presence of significant coronary artery disease (sCAD). Patients in the study with sCAD had a lower RMR compared to patients without, regardless of their risk factors or clinical history of angina, previous myocardial infarction (MI), or angioplasty. These data, published in the current issue of Euro Intervention Journal, demonstrate that RMR was lower...
BURLINGTON, Mass., Feb. 24 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company will be exhibiting at LUMEN 2010, the world's premier ST-elevation myocardial infarction (STEMI) meeting, to be held February 25-27, 2010 at the Loews Miami Beach Hotel in Miami Beach, Florida. The 9(th) Annual LUMEN meeting is an...
BURLINGTON, Mass., Feb. 18 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company's founder and chief executive officer, James E. Muller, M.D., will present and participate in a number of sessions and panel discussions during the annual Cardiovascular Research Technologies (CRT) 2010 meeting. CRT 2010, sponsored...
BURLINGTON, Mass., Feb. 11 /PRNewswire/ -- InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased tissues, today announced that its commercially available LipiScan(TM) Coronary Imaging System will be featured at the Scottsdale Interventional Forum, an international conference for Interventional Cardiologists and other healthcare professionals. The Forum is being held February 11-13 at...
SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract(TM) Thrombus Aspiration Catheter device line from Lumen Biomedical. Volcano became the exclusive global distributor of the Xtract(TM) catheter in May 2009. This acquisition reinforces...
HERZLIYA PITUACH, Israel, February 9 /PRNewswire/ -- SMT Research and Development, Ltd., a privately held company, announced that it has completed its first two clinical cases using the Shimon Embolic Filter [SHEF] (TM). SMT R&D developed a novel technology for brain protection (Neuroprotection) from stroke complication hazards arising from invasive cardiology procedures and heart surgery. The rate of stroke and silent brain damage is the leading severe limiting factor for...
Major study of perfusion imaging under way to assess value of alternative diagnostic methodsCardiologists and heart imaging specialists at 15 medical centers in eight countries, and led by researchers at Johns Hopkins, have enrolled the first dozen patients in a year-long investigation to learn whether the subtle squeezing of blood flow through the inner layers of the heart is better than traditional SPECT nuclear imaging tests and other diagnostic radiology procedures for accurately tracking...
